Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5Business Wire • 01/17/24
Crispr Wins Its Second Gene-Editing Approval In Another Boost To Vertex StockInvestors Business Daily • 01/16/24
Vertex Announces US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta ThalassemiaBusiness Wire • 01/16/24
BetterInvesting™ Magazine Update on Vertex Pharmaceuticals Inc. and Martin Marietta Materials Inc.PRNewsWire • 01/10/24
These 3 Stocks Have Beaten the S&P Average Return for Years and Are Likely to Continue That TrendThe Motley Fool • 01/10/24
What Makes Vertex Pharmaceuticals (VRTX) a Strong Momentum Stock: Buy Now?Zacks Investment Research • 01/09/24
Vertex Pharmaceuticals Incorporated (VRTX) J.P. Morgan 42nd Annual Healthcare ConferenceSeeking Alpha • 01/08/24
January Has Been 1 of the Worst Months for the S&P 500 Over the Last 20 Years. Here Are 3 Stocks to Buy Anyway.The Motley Fool • 01/03/24
Want $1 Million in Retirement? Invest $300,000 in These 3 Stocks and Wait a Decade.The Motley Fool • 12/30/23